Oncogene Science Inc. said Friday that it netted $17.1 million ina secondary offering of 3.68 million shares at $5.50 per share.The shares sold include 200,000 shares sold by a stockholderand underwriter Wertheim Schroder and Co.'s 480,000-shareoverallotment.
After the offering, the Uniondale, N.Y., developer of cancerdiagnostics and therapeutics has 14.9 million sharesoutstanding. The stock (NASDAQ:ONCS) rose 38 cents to $6.63on Friday.
(c) 1997 American Health Consultants. All rights reserved.